Abstract

Glioblastoma is the most aggressive adult primary brain tumor which is incurable despite intensive multimodal treatment. Inter- and intratumoral heterogeneity poses one of the biggest barriers in the diagnosis and treatment of glioblastoma, causing differences in treatment response and outcome. Noninvasive prognostic and predictive tests are highly needed to complement the current armamentarium. Noninvasive testing of glioblastoma uses multiple techniques that can capture the heterogeneity of glioblastoma. This set of diagnostic approaches comprises advanced MRI techniques, nuclear imaging, liquid biopsy, and new integrated approaches including radiogenomics and radiomics. New treatment options such as agents targeted at driver oncogenes and immunotherapy are currently being developed, but benefit for glioblastoma patients still has to be demonstrated. Understanding and unraveling tumor heterogeneity and microenvironment can help to create a treatment regime that is patient-tailored to these specific tumor characteristics. Improved noninvasive tests are crucial to this success. This review discusses multiple diagnostic approaches and their effect on predicting and monitoring treatment response in glioblastoma.
Original languageEnglish
Article number2908609
Number of pages11
JournalDisease Markers
Volume2018
DOIs
Publication statusPublished - 1 Jan 2018

Keywords

  • POSITRON-EMISSION-TOMOGRAPHY
  • HIGH-GRADE GLIOMAS
  • MAGNETIC-RESONANCE-SPECTROSCOPY
  • NEUROONCOLOGY WORKING GROUP
  • POTENTIAL SERUM BIOMARKERS
  • FUNCTIONAL DIFFUSION MAP
  • TRUE TUMOR PROGRESSION
  • BRAIN-TUMORS
  • RECURRENT GLIOMA
  • DIAGNOSTIC-ACCURACY

Fingerprint

Dive into the research topics of 'Noninvasive Glioblastoma Testing: Multimodal Approach to Monitoring and Predicting Treatment Response'. Together they form a unique fingerprint.

Cite this